(Alzheimer Dis Assoc Disord 2016;30:70-72) D eep brain stimulation is an effective and safe treatment option for a variety of medical conditions including Parkinson's disease and essential tremor, and carries a Humanitarian Device Exemption from the FDA for the treatment of dystonia and obsessive compulsive disorder. Recent work has demonstrated the possibility of utilizing deep brain stimulation of the fornix (DBS-f) for the treatment of Alzheimer's disease (AD). [1] [2] [3] We report on a patient with AD who was implanted with DBS-f and subsequently demonstrated asymptomatic bilateral encephalomalacia at the cortical entry sites of the leads.
CASE REPORT
A 48-year-old right-handed man presented with a 9-year history of declining memory and organizational skills that were noticed by the patient, his family, and work associates. Magnetic resonance imaging (MRI) demonstrated mild global cerebral volume loss (Fig. 1A ). The patient was followed at the Johns Hopkins University (JHU) Memory and Alzheimer's Treatment Center as part of the ADvance multicenter Alzheimers Disease DBS trial as a candidate for bilateral DBS-f. This 1-year, delayed-start, doubleblind randomized trial is a feasibility study designed to evaluate the safety, efficacy, and tolerability of DBS-f (ClinicalTrials.gov, NCT01608061; NIH R01-AG042165).
Informed consent was obtained from the patient overseen by a JHU Institutional Review Board. Bilateral DBS-f lead placement was performed in May 2013. A Leksell stereotactic base ring was placed on the patient and MRI was performed for targeting. MRI was stable with respect to imaging 1 month prior. The target was located 2 mm anterior and parallel to the vertical portion of the fornix within the hypothalamus, the most ventral contacts were 2 mm above the optic tract dorsal surface, and approximately 5 mm lateral to the midline bilaterally. 2 Left and right burr holes were drilled according to the planning station-derived coordinate, and arc and ring settings. The final trajectories and lead placements were accepted after autonomic effects (including blood pressure elevation and a sensation of warmth) could be demonstrated beginning at approximately 5 to 7 V of stimulation.
Positron emission tomography (PET) and noncontrast computed tomography (CT) immediately postoperatively demonstrated no evidence of acute territorial infarct, focal mass lesion, or midline shift and confirmed bilateral forniceal electrode placement. MRI 1 day postoperatively also confirmed placement ( Fig. 1B) . Of note, the T2 sequences revealed no hyperintensities or edema along the lead tracts ( Fig. 1F ). The specific absorption rate (SAR) values used for the postoperative MRI are listed in Table 1 .
The later postoperative course was uncomplicated with follow-up visits 1 and 3 months after surgery. Interval CT/PET imaging performed 1 month after implantation demonstrated focal relative decreased FDG uptake identified at the right frontal vertex in a region demonstrating ill-defined hypoattenuation on noncontrast CT images in the area traversed by the right-sided electrode, possibly representing vasogenic edema.
Three months postoperatively, the subject and caregiver reported worsening in cognition accompanied by anxiety and a complaint that his "left side of brain is asleep." The subject was evaluated in clinic and the Alzheimer's Disease Assessment Score-Cognitive 11 Subscale (ADAS-Cog11) score increased (worsened) to 22 from a baseline of 19 but the psychiatric and neurological examinations were unremarkable. MRI demonstrated interval development of cystic encephalomalacia within the frontal lobes just posterior to the deep brain leads, left greater than right (Fig. 1C ). The left cystic region measured 2.56 cm in the AP axis by 1.5 cm wide at its maximum extent and the right cystic region measured 2.12 cm in the AP axis by 1.22 cm wide at its maximum extent with a depth of 3.6 cm. No clinical intervention was taken at this time and the event was reported as an adverse event.
The encephalomalacia cavity was evident on further imaging 6 months postoperatively, however, the cavity on the left had decreased in width by nearly one half, whereas the cavity on the right remained unchanged. An MRV at that time demonstrated a patent sagittal sinus. The patient underwent MRI with and without contrast 1 year and 1 month postoperatively. This demonstrated unchanged position of the DBS leads 4 mm anterior to the fornices with lead tips in the hypothalamus bilaterally. Stable findings of minimal encephalomalacia at the point of entry of the leads into the superior frontal sulci bilaterally were also noted ( Fig. 1D ). SWI sequence imaging at this time also demonstrated no marked areas of hypointensity, indicating no evidence of hemorrhage along the stimulating lead tracks.
DISCUSSION
Deep brain stimulation of the fornix may provide a new avenue for improving the symptoms of AD, a goal that has so far eluded the scientific community. The impetus for DBS-f came from a case report demonstrating induced enhancement of memory in a patient implanted in the hypothalamus near the fornix for treatment of his obesity. 1 An open-label pilot study of DBS in AD demonstrated possible slowing of cognitive decline and improvement in glucose utilization. 2, 3 In addition, there is evidence that the structural integrity of the fornix predicts cognitive and functional decline in prodromal AD. 4 These efforts led to a larger randomized clinical trial, the ADvance Study, to assess the efficacy of DBS-f for the treatment of AD. This report details an adverse event wherein 1 patient demonstrated bilateral encephalomalacia at the cortical entry site of the DBS leads on delayed postoperative imaging while, to date, remaining clinically asymptomatic.
Encephalomalacia is a known, but relatively rare, postsurgical complication of DBS lead implantation. 5, 6 Retrospective studies have estimated the incidence of encephalomalacia at around 4.2%. 6 Instances of encephalomalacia are usually unilateral as opposed to the bilateral nature of the event here. In these cases, encephalomalacia was not evident immediately postoperatively but on scans an average of 19 months postoperatively. In most of these cases, immediate MRI had shown intraparenchymal hemorrhage or edema. 6 The ADvance trial includes 42 participants implanted bilaterally yielding 84 DBS-f implantation sites. To date, no other patient implanted with DBS-f for AD has demonstrated encephalomalacia on postoperative imaging, including 6 patients implanted for a phase I clinical trial focused on safety. Including our patient, the incidence of encephalomalacia in DBS-f is 2.1% per side (2/ 96). Although this rate is lower than that reported with DBS for Parkinson's disease, it is too early in the implementation of DBS-f, with too few patients implanted, to provide conclusive rates.
Beyond the standard operative risk, other potential mechanisms for encephalomalacia in this case include side effects of MRI and vascular complications. A large number of clinical series and animal in vivo testing has demonstrated the safety of MRI postoperatively in patients implanted with DBS. 6, 7 These studies have focused on several specific features of the MRI process including the SAR value, the DBS configuration, Tesla strength of the MRI, the RF coils, and the gradient. These reviews, and Medtronic's own recommendations, limit the average SAR to 0.1 W/kg. Of note, there have been 2 case reports demonstrating neurological sequelae postimaging, including hemorrhage, aphasia, and dystonia. In the case of 7 In the current patient, the immediate postoperative imaging exceeded this average SAR value for 2 sequences ( Table 1 ). The SAR values for these 2 sequences (0.28 and 0.26 W/kg) were still below the original upper limit of 0.4 W/kg set by the lead manufacturer. Some research groups have shown safety of scanning with SAR values in excess of 0.1 W/kg. SAR values up to 0.8 W/kg have been used in 96 patients in 192 MRIs without adverse effects. 6 Early postoperative imaging showed no evidence of acute territorial infarct (Fig. 1B) . Susceptibility weighted imaging scans after 1 year demonstrated no hypodensities, reinforcing the lack of evidence for tract hemorrhage. A review of the imaging findings by neurosurgeons at the clinical site and at other sites in the trial suggested (but not unanimously) the encephalomalacia may have been caused by a stroke secondary to venous thrombosis of the superior sagittal sinus initiated during the DBS lead implantations, but other neurosurgeons in the trial did not agree on this interpretation.
Venous thrombosis leading to infarction and delayed neurological decline is a rare (< 1/100 patients), but serious adverse event of DBS implantation. [8] [9] [10] Although an MRV demonstrated a patent superior sagittal sinus 6 months postoperatively, this was 2 months after the patient's clinical symptoms and the venous stasis may have resolved by that point and therefore no conclusive imaging of venous infarction were obtained. Imaging in favor of venous infarction includes CT imaging performed 1 month postoperatively that demonstrated an area of possible vasogenic edema in the right frontal region as well as the bilateral nature and location of the lesions near the midline sagittal sinus.
CONCLUSIONS
We report bilateral encephalomalacia in a patient implanted with DBS-f for AD. A venous infarct either in the superior sagittal sinus or bilateral cortical venous structures most likely caused this. However, other factors may have contributed such as an elevated SAR during MRI. DBS-f is being studied for use in AD with potential wide scale implementation impacting thousands of patients. Therefore, further study is warranted into this and other possible adverse effects of DBS-f in patients with AD.
